Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Neurosci ; 53(2): 376-389, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32979866

RESUMEN

The mechanism underlying the role of tumor necrosis factor alpha (TNF-α) in the development of inflammatory hyperalgesia has been extensively studied, mainly the role of TNF-α in the release of pro-inflammatory cytokines. The current concept relies in the fact that TNF-α stimulates the cascade release of other pro-inflammatory cytokines, such as IL-1ß, IL-6, and IL-8 (CINC-1 in rats), triggering the release of the final inflammatory mediator prostaglandin E2 (PGE2 ) and sympathetic amines that directly sensitize the nociceptors. However, this may not be the sole mechanism involved as the blockade of TNF-α synthesis by thalidomide prevents hyperalgesia without interrupting the synthesis of IL-1ß, IL-6, and CINC-1. Therefore, we hypothesized that activation of TNF-α receptor type 1 (TNFR1) by TNF-α increases nociceptors' susceptibility to the action of PGE2 and dopamine. We have found out that intrathecal administration of oligodeoxynucleotide-antisense (ODN-AS) against TNFR1 or thalidomide prevented carrageenan-induced hyperalgesia. The co-administration of TNF-α with a subthreshold dose of PGE2 or dopamine that does not induce hyperalgesia by itself in the hind paw of Wistar rats pretreated with dexamethasone (to prevent the endogenous release of cytokines) induced a robust hyperalgesia that was prevented by intrathecal treatment with ODN-AS against TNFR1. We consider that the activation of neuronal TNFR1 by TNF-α decisively increases the susceptibility of the peripheral afferent neuron to the action of final inflammatory mediators - PGE2 and dopamine - that ultimately induce hyperalgesia. This mechanism may also underlie the analgesic action of thalidomide.


Asunto(s)
Receptores Tipo I de Factores de Necrosis Tumoral , Factor de Necrosis Tumoral alfa , Animales , Citocinas , Hiperalgesia/inducido químicamente , Neuronas Aferentes , Dolor , Ratas , Ratas Wistar
2.
Trends Pharmacol Sci ; 39(12): 1000-1002, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30454767

RESUMEN

Management of pain is a fundamental imperative in medicine. Current analgesics suffer from limitations related to efficacy and adverse events of which abuse potential has assumed an important role. Here we highlight the factors that drive the development of novel analgesics and the advances made in the field.


Asunto(s)
Analgésicos Opioides/efectos adversos , Descubrimiento de Drogas , Epidemias/prevención & control , Trastornos Relacionados con Opioides/tratamiento farmacológico , Analgésicos Opioides/síntesis química , Analgésicos Opioides/uso terapéutico , Humanos , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA